Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 3/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | LDHB | P07195 | 2/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12132356 | 1.00 | DHODH (0.44) | DHODHPRKD1AXLMERTKMAPK14 | |
| SCHEMBL1347870 | 0.88 | DHODH (0.44) | DHODHPRKD1AXLMERTKFYN | |
| SCHEMBL1347868 | 0.88 | DHODH (0.44) | DHODHPRKD1AXLMERTKFYN | |
| SCHEMBL1348035 | 0.86 | OPRM1 (0.45) | DHODHPRKD1AXLMERTKFYN | |
| SCHEMBL1347565 | 0.85 | PRKD1 (0.48) | PRKD1FYNCD274LDHBLDHA | |
| SCHEMBL1348071 | 0.85 | PRKD1 (0.48) | PRKD1FYNCD274LDHBLDHA | |
| SCHEMBL1347566 | 0.85 | PRKD1 (0.48) | PRKD1FYNCD274LDHBLDHA | |
| SCHEMBL1347356 | 0.83 | PRKD1 (0.44) | PRKD1MAPK14CD274KDM1APRKD3 | |
| SCHEMBL1347793 | 0.76 | DHODH (0.44) | DHODHMAPK14FYNLDHBLDHA | |
| SCHEMBL1348274 | 0.74 | KDM1A (0.49) | PRKD1AXLMERTKFYNCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | claimed |
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | DHODH 2467/4885PRKD1 4556/4885AXL 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.